Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer

Abstract

Androgen deprivation therapy (ADT) resulting in testosterone suppression is central to the management of prostate cancer (PC). As PC incidence increases, ADT is more frequently prescribed, and for longer periods of time as survival improves. Initial approaches to ADT included orchiectomy or oral estrogen (diethylstilbestrol [DES]). DES reduces PC-specific mortality, but causes substantial cardiovascular (CV) toxicity. Currently, luteinizing hormone-releasing hormone agonists (LHRHa) are mainly used; they produce low levels of both testosterone and estrogen (as estrogen in men results from the aromatization of testosterone), and many toxicities including osteoporosis, fractures, hot flashes, erectile dysfunction, muscle weakness, increased risk for diabetes, changes in body composition, and CV toxicity. An alternative approach is parenteral estrogen, it suppresses testosterone, appears to mitigate the CV complications of oral estrogen by avoiding first-pass hepatic metabolism, and avoids complications caused by estrogen deprivation. Recent research on the toxicity of ADT and the rationale for revisiting parenteral estrogen is discussed.

Keywords: LHRH agonist; PATCH trial; Prostate cancer; androgen deprivation therapy (ADT); estrogen; testosterone.

Figures

Figure 1. Toxicities Associated with Androgen Deprivation Therapy Attributed to Sex Hormone Deficiency

Figure 2. Prostate Adenocarcinoma Trans Cutaneous Hormones Trial Schema

*Includes patients enrolled from the first stage, apart for the first 50 patients randomized before the initial patch dose regime change. LHRH = luteinizing hormone-releasing hormone.